Because hypoxia is also linked to NSCLC therapy resistance, there are several approaches to target hypoxia via increasing hypoxic cell radiation sensitivity (misonidazole, nimorazole), increasing oxygen delivery (carbogen, nicotinamide, efaproxiral), decreasing oxygen consumption (metformin, atovaquone), specific targeting of hypoxic cells using hypoxia-activated cytotoxic prodrugs (tirapazamine, evofosfamide, tarloxotinib bromide), hypoxia molecular target inhibitors (aryl sulfonamides targets, HIF-1α gene products) and various other hypoxia-related mechanisms (nitroglycerin, BKM120) [11]. The gene discussed is HIF1A; the disease is non-small cell lung carcinoma.